Showing 3361-3370 of 4063 results for "".
- Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programshttps://modernod.com/news/glaukos-announces-positive-clinical-updates-for-several-corneal-health-pipeline-programs/2481343/Glaukos announced positive clinical updates for several of its corneal health pipeline programs, including the commencement of subject enrollment in a second phase 3 confirmatory trial for Epioxa (Epi-on), and initial results from the company’s phase 2a clinical trial for GLK-301
- Market Scope: Lens-Based Procedures Will Push Retail Refractive Surgery Market to $12 Billionhttps://modernod.com/news/market-scope-lens-based-procedures-will-push-retail-refractive-surgery-market-to-12-billion/2481338/Market Scope forecasts that the global refractive surgery industry will generate $12 billion in total retail revenue in 2027—up from $8.9 billion in 2022—for a compound growth rate of 6.2 percent. The health care research company expects revenue at the manufacturer level to
- Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officerhttps://modernod.com/news/alimera-sciences-appoints-industry-veteran-russell-l-skibsted-as-chief-financial-officer/2481331/Alimera Sciences announced the appointment of Russell L. Skibsted as Senior Vice President and Chief Financial Officer (CFO), effective January 9, 2023. “We are extremely excited to have someone of Russell’s caliber join us here at Alimera,” Rick Eiswirth, P
- Shamir Glacier Plus Metaform on Transitions Signature GEN 8 Brown and Grey Now Availablehttps://modernod.com/news/shamir-glacier-plus-metaform-on-transitions-signature-gen-8-brown-and-grey-now-available/2481325/Shamir announced the launch of Shamir Glacier Plus Metaform, a new lens coating that is designed to remove compromises experienced with other lenses. According to Shamir, features of the coating include: Up to 20% thinner & lighter t
- Apellis Appoints Caroline Baumal, MD, as Chief Medical Officerhttps://modernod.com/news/apellis-appoints-caroline-baumal-md-as-chief-medical-officer/2481321/Apellis Pharmaceuticals announced that retina specialist Caroline Baumal, MD, has joined Apellis as chief medical officer. Dr. Baumal replaces Federico Grossi, MD, PhD, who plans to remain at Apellis until February 28, 2023 to help with the transition and preparations for the potential launc
- EyePoint Pharmaceuticals Promotes Jay S. Duker, MD, to President and Chief Operating Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-promotes-jay-s-duker-md-to-president-and-chief-operating-officer/2481320/EyePoint Pharmaceuticals announced that Jay S. Duker, MD, who has served as the company’s Chief Operating Officer (COO) since November 2021, has been promoted to the additional role of President. In addition to continuing to oversee his duties as COO, in his expanded role, Dr. Duker wi
- Mobius Therapeutics Granted New US Patent for Injected Ophthalmic Mitomycin-Chttps://modernod.com/news/mobius-therapeutics-granted-new-us-patent-for-injected-ophthalmic-mitomycin-c/2481319/Mobius Therapeutics has been issued US Patent #11,540,977, "Injection Apparatus and Method of Use," protecting future applications of Mitosol, Mobius’ flagship product, particularly versus compounded, unapproved copies of Mitosol. “This is an important ad
- Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directorshttps://modernod.com/news/iveric-bio-announces-the-addition-of-pravin-u-dugel-md-to-its-board-of-directors/2481317/Iveric bio announced the election of Pravin U. Dugel, MD, President of Iveric Bio, to its Board of Directors, effective as of January 1, 2023. Dr. Dugel has been instrumental in helping to shape the company’s business strategy and in overseeing the development and regulatory submission
- Staar Surgical CEO Caren Mason to Retire; Tom Frinzi Appointed New CEOhttps://modernod.com/news/staar-surgical-ceo-caren-mason-to-retire-tom-frinzi-appointed-new-ceo/2481302/Staar Surgical announced that President and Chief Executive Officer Caren Mason will be retiring December 31, 2022, after serving in that postion for 7 years. Staar's Board of Directors has appointed ophthalmic industry executive Thomas G. Frinzi, current Board Chair of Staar,
- Improved PC-IOL Technology is Key to Recent and Future Premium Cataract Surgery Growthhttps://modernod.com/news/improved-pc-iol-technology-is-key-to-recent-and-future-premium-cataract-surgery-growth/2481273/Presbyopia-correcting IOL technology improvements have led to almost a doubling of global units over the past 5 years and will be critical to driving future growth over the next 5 years, according to a Market Scope report. In 2022, PC-IOLs will represent nearly 55 percent of premi